Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a report released on Tuesday.

Separately, HC Wainwright restated a neutral rating on shares of Oramed Pharmaceuticals in a research report on Monday.

Oramed Pharmaceuticals Stock Down 0.4 %

Shares of ORMP stock opened at $2.40 on Tuesday. The company has a market cap of $97.85 million, a P/E ratio of 9.23 and a beta of 1.77. The business has a 50 day moving average of $2.44 and a two-hundred day moving average of $2.51. Oramed Pharmaceuticals has a 52 week low of $1.67 and a 52 week high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.21. Analysts expect that Oramed Pharmaceuticals will post 0.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. acquired a new stake in Oramed Pharmaceuticals in the 1st quarter valued at approximately $54,000. Murchinson Ltd. grew its stake in shares of Oramed Pharmaceuticals by 31.4% in the first quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock worth $4,028,000 after purchasing an additional 329,495 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Oramed Pharmaceuticals during the first quarter valued at $68,000. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.